What is Nano-OligoMed?

We are an European MSCA Research and Innovation Staff Exchange (RISE) network started at the end of 2017. Nano-Oligomed: Hybrid Nanostructured Oligonucleotide Platforms for Biomedical Applications, H2020-MSCA-RISE-778133

What is a RISE action?

Research and Innovation Staff Exchange (RISE) funds short-term exchanges of staff between academic and productive sectors in and out Europe.

It promotes the development and exchange of knowledge and skills between different academic and non-academic groups with complementary expertise in the quest for solving social impacting problems.

What are the objectives of Nano-OligoMed?

Nano-OligoMed has the ambition to establish and support a network of international exchange, enabling a collaborative scientific team to effectively use a diversity of approaches and strategies to generate and test hybrid nanomaterials for the efficient and safe systemic delivery of oligonucleotide-based therapeutic agents. To this end, we have set-up a joint multidisciplinary scientific collaborative program between 4 European and 3 extra-European institutions, that through exchange, international mobility, and strongly collaborative transfer of knowledge and training activities will bring together leading experts under the field of nanomaterials in biomedicine. The scientific aim of Nano-OligoMed is the creation of degradable hybrid structures that combine different nanostructured materials, as silica, silicon and quatsomes with the delicate programmable oligonucleotides or artificial oligonucleotide-mimic structures. The possibility to develop novel oligonucleotide-based materials will enable a) the degradation of the drug carrier at the presence of a specific input as a function of the intrinsic bio-responsive feature of oligonucleotides, b) the activation of a therapeutic function as a result of the bio-molecular interaction between the oligonucleotide-based material and the molecular target (i.e. miRNAs) and c) the delivery of the chemical payload (DNA and/or artificial mimics, even in combination with cancer drugs) upon cell internalization. The international academic networking possessing  a diversity of research skills and the educational activities, will provide to young (PhD students) and senior scientists, specific competences in the field of materials science, nanotechnology, molecular biology and molecular medicine.

Partner organizations

Seven organizations based in six different countries participate in the Nano-OligoMed Project: 

University of Strasbourg


University of Rome Tor Vergata


Nanomol Technologies